Budesonide And Formoterol Fumarate Dihydrate Aerosol
Product Images NDC 85766-113

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Budesonide And Formoterol Fumarate Dihydrate (NDC 85766-113). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sportpharm Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

15 (308708 Rapihaler Counter 15 (black 130 485))

FDA Label Image

80 (308710 Rapihaler Counter 80 (black 130 485))

FDA Label Image

Figure 1 (Figure1bodytext)

FDA Label Image

Figure 2 (Figure2bodytext)

FDA Label Image

Figure 3 (Figure3bodytext)

FDA Label Image

Figure 4 (Figure4bodytext)

This data provides information on the percent change from baseline in FEV over a period of 12 hours. The study is linked to the use of Budesonide and Formoterol Fumarate Dihydrate inhalation with specific dosages. It involves monitoring FEV levels at different time points and under various dosing regimens, including predose FEV measurements and final visit evaluations. The text indicates a detailed analysis of the impact of these medications on FEV levels over the specified time frame.*

FDA Label Image

Figure 5 (Figure5bodytext)

This text appears to contain information regarding the assessment of patients taking different treatments, specifically Budesonide and Formoterol Fumarate Dihydrate 80/4.5mcg and Budesonide 80mg. The data includes the number of patients assessed at various time points. Budesonide and Formoterol Fumarate Dihydrate 80/4.5mcg is administered as two inhalations twice daily, while Budesonide 80mcg is also administered as two inhalations twice daily.*

FDA Label Image

Figure 6 (Figure6bodytext)

This text appears to provide data on the percent change from baseline in pre-dose FEV in relation to different medications and doses. It includes details on Budesonide and Formoterol Fumarate Dihydrate in various strengths, as well as a placebo. The text also mentions the dosing regimen of each medication.*

FDA Label Image

Figure 7 (Figure7bodytext)

This text provides data on a study evaluating the percent change from baseline in 1-hour post-dose FEV in individuals using different medication regimens including Budesonide and Formoterol Fumarate in various doses, as well as a placebo group. The study tracked measurements over different time points, including at the end of treatment, and it appears that the study durations included at least 6 months. Various inhalation dosages and frequencies were compared across the treatment groups.*

FDA Label Image

Budesonide Structural Formula (Image 01)

FDA Label Image

Structural Fumarate (Image 02)

FDA Label Image

Figure 1 (Image 03)

This text appears to describe a counter with a canister inside for water, a mouthpiece, a strap, and a mouthpiece cover. It is likely referring to some sort of equipment or device used for measuring or counting. The figure 1 suggests that there might be accompanying illustrations or diagrams.*

FDA Label Image

Figure 2 Gray Arrows (Image 04)

FDA Label Image

Figure 3 (Image 05)

FDA Label Image

Figure 4 (Image 06)

FDA Label Image

Figure 5 (Image 07)

FDA Label Image

16 (Label 16)

FDA Label Image

80 (Label 80)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.